Yearly Archives: 2021


Brave New World is being reinvented with synthetic embryosand the right reasons – SYFY WIRE

In his 1932 novel Brave New World, Aldous Huxley walks you into a terrifying lab where human embryos and fetuses are being grown in glass containers and genetically engineered to fit into a certain rank of society. It continues to be nightmare fuel for college students everywhere.

Now that we live in an era where science fiction is morphing into science, conceiving artificial embryos sounds like an incarnation of the bookbut couldnt be further from it. Scientists have proven it is possible to synthetically create embryos from stem cells. This is a viable and ethical alternative to studying human or animal embryos, and a new frontier in finding out more about how preimplantation embryos may mutate or fail.

Instead of trying to build a societal hierarchy from human beings born in vitro, researchers Cody Kime, Kiichiro Tomoda and their team from Kyoto University and the RIKEN Center for Biosystems Dynamics Research are using their findings in an effort to find out what can go wrong with embryos in their earliest phases and cause early pregnancy loss. They recently published a study inStem Cell Reportsandare optimistic that the glitches of nature can someday be prevented.

"As you can imagine, there is tremendous power, inevitable risk, and serious ethical responsibility, although using cultured cells we can greatly reduce animal experiments. Perhaps one of the best applications is screening genetic mutations that impede fertility and reproduction,"Kime told SYFY WIRE. "if those mutations are tolerated in our starting stem cell population, we can initiate reprogramming, and see how those mutations affect the synthetic embryo system. From there, we can get a better picture of how those genes may affect human fertility and improve on treatments."

If organoids (even the brain) can be grown for further research, so can embryoids. The team, whose in vitro synthetic embryo systems (SESs)came from mouse stem cells, was trying to successfully recreate totipotency, meaning that the cells would have everything they needed to develop into a whole organism. Totipotency does not last long in embryonic stem cells. Pluripotency, which is the ability to produce some types of necessary cells, but not all, is much easier to achieve. This is still a positive. If the stem cells are at least pluripotent, it might be possible to reprogram them to be totipotent.

There are three types of cells needed for totipotency to happen. They need to be able to generate the embryo, the placenta and the amniotic sac. This is such a fleeting state in mammals because the cells in the embryo multiply and polarize fast to turn into one of those three things.Kime and Tomoda didnt try to do everything at once. The team started by growing pluripotent mouse cells, or epiblast stem cells, responsible for only the fetus. Pluripotent pre-implantation epiblast stem cells are capable of arranging themselves into what at least looks like an embryo before it implants. If they could somehow hit the rewind button on those cells, they would revert them back to a stage before they specialized in just the fetus, the totipotent phase.

"We have seen evidence that something like totipotency may be happening in our reprogramming system, and it arises by taking a later stage embryonic stem cell and treating it with specific natural molecules and nutrients," Kime said."In a way the cell is tricked to reprogram and gain the ability to form the other embryonic lineages."

Reprogramming meant that the scientists would need to be able to tell which genes each cell turned on oroff. They used a process called RNA sequencing, which sees how much RNA is and how many sequences of that RNA is in a sample. RNA (ribonucleic acid) tells DNA how to put together different proteins. Sequencing reveals its transcriptome, or everything that makes up RNA, and allows scientists to better understand cells up close. They observed the gene expression in thousands of cells, which told themwhich cells could be potentially reprogrammed to become totipotent. Hi-res regulation of gene expression could even show what ways cells were changing.It took Kime 5 days of reprogramming attempts, but some of the past epiblast stem cells (EPISCs) finally got there.

The analysis revealed that cells resembling all three types of the early embryo were generated by our unique reprogramming system at the same time," he said. "Our analysis showed, in great detail, that our reprogrammed cells had engaged nearly all early embryo cells, while turning off the genes of the cell type they came from. The most important analysis was comparing our reprogrammed cells to real embryonic cells and finding that, across incredibly rich data, our cells were nearly identical."

The breakthrough has given Kime, Tomoda and their team a portal into what was once unthinkable. Because epiblast stem cells are easily reproduced, they can carry out studies on a much larger scale. They will also be able to explore things that would have not been considered ethical otherwise, such as getting a more in-depth look at how reprogramming happens and screening for gene mutations and other things that could cause a pregnancy to terminate itself. So while their work may be venturing into a brave new world, the intent is the total opposite of the sinister motives in Brave New World.

Whether strawberry ice cream soma will ever be a thing still remains to be seen.

Here is the original post:
Brave New World is being reinvented with synthetic embryosand the right reasons - SYFY WIRE

Stem Cell Therapy Market Trends Evaluation 2021 By Leading Players Updates, Consumer-Demand, Key Strategies, Consumption, Industry Development, Market…

The report offers information on the variety of products and services provided in the market, covering a multitude of operations and activities throughout the global Stem Cell Therapy market value chain. The study analyzes the world Stem Cell Therapy market in terms of production, income, sectoral structure, and export and trade activities. Moreover, technological tendencies in the global Stem Cell Therapy market have been put forward. The growth rate of the market in developed countries like Mexico, Brazil, Argentina, Australia, the EU, Canada, the USA, and in developing countries like India and China is studied in detail. The most important technological advancements in the market are presented in the study.

Get Exclusive Sample of Report on Stem Cell Therapy market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

Report Introduction:

The report shows market-driven results providing feasibility studies for client requirements. The research covers qualified and verifiable aspects of the global Stem Cell Therapy market. The client requirements are ensured by providing a thorough understanding of market capacities in the real-time scenario. The report examines the profiles of prominent market players, highlighting ratio, capacity, production, revenue, and consumption in terms of geographical areas. The research report has used the numbers and figures in a comprehensive manner with the help of graphical and pictorial representation which represents more clarity on the market.

Browse the Short Summary & TOC of the Report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Points Covered in the Report

1. Economic and trade-related activities in the global Stem Cell Therapy market. 2. Changes in production systems over the years. 3. The future of the global Stem Cell Therapy market, trends, and challenges. 4. Productivity growth constraints. 5. The shift in consumer preferences and key factors changing the market dynamics. 6. Current and anticipated market size and CAGR in USD billion. 7. Key features and growth rate of the global Stem Cell Therapy industry worldwide. 8. Macro outlook and industry outlook. 9. Market landscape pertaining to the global Stem Cell Therapy market selected countries. 10. Trade scenarios, major export destinations, major countries of import. 11. Digital initiatives by the leading players for capacity building and boosting operational efficiency. 12. Quality, serviceability, financial, policy-related, capacity building constraints associated with the unorganized manufacturers in the market. 13. The report summarizes export opportunities in selected markets.

Stem Cell Therapy Market Analysis by Key Segmentations

By type, Stem Cell Therapy Market is segmented as:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

By Applications, Stem Cell Therapy Market is segmented as:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The international trade, investment, and export promotional strategies implemented by the industrialists, traders, and investors to strengthen the global economic competitiveness are included in the report. The knowledge on these developments given in the report unlocks export and investment opportunities for the stakeholder and other participants in the industry. Quantitative and qualitative analysis to combine the results is done. This study groups the export markets for the products and services in the global Stem Cell Therapy market into three categories: Strategic, Dynamic Growth, and Long-Term Opportunity.

These export markets are ranked based on the criteria including volume ranking, growth ranking, and performance ranking. The volume ranking ranks the global export markets by dollar value, highest to lowest whereas the growth ranking is based on the averaging the Compound Annual Growth Rate (CAGR) of these markets for the years 2010-2015 and 2016-2020. The CAGR of the years 2016-2020 is included to capture the more recent developments. And, performance ranking globally is based on the exports of the main categories. The global commodity prices and the other factors influencing the corresponding categories are taken into consideration. The major driving powers of technological trends such as market, manufacturers, and legislation are studied in detail.

The gist of the report highlights is as follows:

1. This report covers a comprehensive market overview presenting the competitive market scenario among key players, understanding their growth opportunities, and business strategies 2. The factors contributing to the growth, market risks, growth restraining factors are analyzed in this report to help other players in making an informed decision 3. The five-year forecast information will pave the way for futuristic developments and expected market growth 4. A thorough analysis of key Stem Cell Therapy product segments, changing market dynamics will lead to complete market study 5. This research study serves as a complete guide which provides valuable insights and in-depth analysis of various industry verticals

TOC of Stem Cell Therapy Market Report Includes:

1. Industry Overview of Stem Cell Therapy 2. Industry Chain Analysis of Stem Cell Therapy 3. Manufacturing Technology of Stem Cell Therapy 4. Major Manufacturers Analysis of Stem Cell Therapy 5. Global Productions, Revenue and Price Analysis of Stem Cell Therapy by Regions, Creators, Types and Applications 6. Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Stem Cell Therapy 2015-2020 7. Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Stem Cell Therapy by Regions 8. Gross and Gross Margin Examination of Stem Cell Therapy 9. Marketing Traders or Distributor Examination of Stem Cell Therapy 10. Worldwide Impacts on Stem Cell Therapy Industry 11. Development Trend Analysis of Stem Cell Therapy 12. Contact information of Stem Cell Therapy 13. New Project Investment Feasibility Analysis of Stem Cell Therapy 14. Conclusion of the Global Stem Cell Therapy Industry 2020 Market Research Report Continued

Make an Enquiry before Buying @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Originally posted here:
Stem Cell Therapy Market Trends Evaluation 2021 By Leading Players Updates, Consumer-Demand, Key Strategies, Consumption, Industry Development, Market...

STEM NOLA Teams with Obatala Science & CellSpring to Expose Students to Careers and Medical Research at Biotech Startups – PRNewswire

NEW ORLEANS, April 30, 2021 /PRNewswire/ --STEM NOLA is proud to partner with Obatala Sciences and CellSpring to engage at least a dozen high school students from the greater New Orleans area in a series of courses that will expose teens to careers in biotechnology startup companies. This extraordinary program focuses on providing high school students with exposure-rich, hands-on opportunities to engage deeply in work in the realm of STEM.

Over the course of three Saturday sessions on May 8, 15 and 22, students will receive comprehensive lab exposure to the work at both companies involving tissue engineering, stem cell research (stem cells isolated from adult fat tissue), and preclinical evaluation of potential therapeutics. Students will learn the route that new medicines and treatments take to the clinic and the steps that ensure they are safe. Further, students will learn the role that tissue engineering plays in improving the testing of new drugs.

"We are exceedingly grateful and incredibly proud to partner with both Obatala Sciences and CellSpring to expose our future innovators to the advancements being made in biotechnology research," said STEM NOLA CEO Dr. Calvin Mackie. "This type of engagement with professionals who do this work on a daily basis is life changing. It will continue building on the interest and promise these students have already shown in STEM fields."

Dr. Mackie, a former tenured Tulane Engineering professor, founded STEM NOLA in 2014 to expose, inspire and engage communities in learning opportunities in Science, Technology, Engineering and Mathematics (STEM). The award-winning programming designs and delivers activities, programs and events. Since 2014, STEM NOLA has engaged more than 65,000 students - mostly underserved students of color - in hands-on STEM project-based learning.

"Obatala welcomes this opportunity to advance STEM NOLA's core mission and promote STEM education in our community," said Obatala Sciences Chief Scientific Officer, Dr. Jeffrey Gimble. "We are excited to have a chance to instruct and learn from the next generation of home-grown scientists recruited from our local high schools. By investing in their future, we are guaranteeing that biotech companies like ours will have a pipeline of talent to draw on in years to come."

Obatala Sciences' CEO, Dr. Trivia Frazier, agreed, saying, "We are proud to work with STEM NOLA on this project and are excited to see Dr. Mackie's continued progress building this organization."

Founded in 2017, Obatala Sciences is a biotechnology company that offers research products and services to scientists in medical industries and academia with the goal of advancing tissue engineering and regenerative medicine. Obatala makes high-quality products that researchers use to discover better therapies for diseases like obesity and diabetes that significantly impact the human population.

CellSpringdevelops blood tests to screen at-risk patients for cancer with the goal of significantly shifting the timing of a diagnosis to earlier stages. CellSpring's tests are based on a proprietary technology that effectively 'tricks' cancer cells into revealing the molecular makeup of small particles, called exosomes, that secrete into the blood. "We are proud of the work that STEM NOLA does to bring exposure, access, and opportunity to young innovators," said Dr. Christopher Millan, CellSpring CEO. "I am thrilled to have this chance to contribute to that work, and collaborating with good friends at Obatala."

Dr. Queralt Vallmaj-Martn, CELLSpring's postdoctoral researcher, added, "I'm very excited to share with NOLA high school students our passion for science and introduce them to the fascinating world of biomaterials and stem cells. Our goal is to spark inspiration in these students to discover the unknown and see that the scientific world has a great deal to offer for personal and professional development. Looking forward to our Saturdays together!"

(To interview Calvin Mackie, contact Michael K. Frisby, [emailprotected]or 202-625-4328.)

Contact:Michael K. Frisby [emailprotected] 202-625-4328

Casey Ferrand [emailprotected] (504) 810-3565

SOURCE STEM NOLA

Original post:
STEM NOLA Teams with Obatala Science & CellSpring to Expose Students to Careers and Medical Research at Biotech Startups - PRNewswire

Breakthrough gene therapies in sight | UNC-Chapel Hill – UNC Chapell Hill

Patients withgeneticlysosomal storagediseases particularly children are living longer because of better treatments. But with promising advances and longer lives comes complications, the loss of eyesight as these rare diseases take their toll over time.

Lysosomal storage diseases are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the bodys cells as a result of enzyme deficiencies, according to theNational Organization for Rare Disorders. With these diseases, patients are missing the mucopolysaccharidosis type 1 (MPS1) gene. Current therapies that allow patients to live longer dont address corneal clouding caused by these diseases. However, one Carolina-affiliated startup, RainBio, isdeveloping anovel gene therapyforMPSI corneal blindness, giving patients a chance not only for longer lives but better ones.

The companys treatment, RBIO-1, is poised to meet a large unmet medical need in ophthalmology.Co-foundedbyMatt Hirsch,associate professor of ophthalmology at the UNC Gene Therapy Center, RainBio is the only ocular gene therapy pioneer focused on blindness in the cornea. The companys adeno-associated virus vector gene therapy can directly correct cornea cellular function to maintain or restore vision in patients at risk of blindness. The companys first candidate is a groundbreaking, first-in-class lead program for corneal clouding in MPS1 patients who have vision loss.

As we look at what is being done in the ophthalmology space, we see that most [adeno-associated virus] therapeutics are focused on the back of the eye the retina, but nobody seems to be looking at the front of the eye the cornea, says Fran Martin, RainBio president. If we can provide those affected with lysosomal storage diseases a mechanism where they can see, theyd be able to have a better quality of life.

The idea for RainBios treatment started less than five years ago, when Dr. Joanne Kurtzberg, a pediatric bone marrow transplant specialist, who conducts stem cell transplants in children with lysosomal storage diseases at Duke, met with Hirsch and Samulski to figure out how to potentially address the blindness that comes with lysosomal storage disease. Kurtzberg works with stem cell therapies that can extend the longevity of life for kids affected but dont address the loss of sight. Hirsch realized if he could replace the missing gene in the cornea, those kids could regain their sight.

With our product, you inject the missing gene right into the cornea, says Martin. This allows for prevention of corneal clouding or blindness, and can even reverse the blindness or cornea clouding if the treatment is given early enough.

For kids who are losing their sight, another option is to have a cornea transplant. But those transplants dont come without risk.

Corneal transplants can sometimes result in high rejection rates and potential infection, adds Martin. We can offer an additional treatment that patients can try before moving to a transplant.

The RainBio team often collaborates with colleagues at local universities as well asJoseph Muenzer,a professor of pediatric genetics and metabolism at the School of Medicine, who treats children affected bylysosomal storage diseases.Jude Samulski, professor of pharmacology at the Gene Therapy Center in the UNC School of Medicine and a pioneer in gene therapy, also contributed to the patents for the product.

A lot of expertise in gene therapy was developed over the past few decades at UNC, says Martin. That expertise has benefited RainBio, and weve benefited from the input into the science around our product as well.

To make the best use of resources, the RainBio team benefits from collaborating withKickStart Venture Services as well as Carolinas Office of Technology Commercialization. KickStart supports faculty startup formation, business development and growth by providing coaching and mentoring, early-stage funding, connection with key service providers, management, investors and space. Both KickStart and the Office of Technology Commercialization. are part of Innovate Carolina, the University-wide initiative for innovation and entrepreneurship.

Its been a pleasure to work with KickStart and OTC to really get the guidance and resources needed as weve grown as a company, says Martin. They helped us work through the Carolina Express License and have been very supportive in helping us to understand the process as well as in providing resources as we think through our strategy as a growing company.

The Carolina Express license assists Carolina startups by streamlining and speeding the path for UNC-Chapel Hill faculty, students or staff startup founders to translate new discoveries into useful products.

Alongside Epigenos Bioscience, the RainBio team also had the opportunity in fall 2020 to present to approximately 20 advisors who gave them advice on how to continue commercializing their technology and growing their business, even in the midst of a pandemic. This is one of the programs that Kickstart adapted online to continue providing support for startups. Advice and guidance offered at advisory meetings includes anything from R&D to fundraising and strategy. Other startup companies that would like to present can get in touch with KickStart to be considered for a future meeting.

In addition, RainBio received a $100,000 loan fromNCBiotechas well as support from theMPS Society, which funded a key rabbit toxicology study. RainBio also collaborated with NC State University through co-founderBrian Gilger, who has conducted the toxicology studies at the NC State School of Veterinary Medicine.

And for patients who are ready to try RainBiosRBIO-1 treatment,Martin says the idea of a one-time dose is promising.

Although we are still testing the product, whats also unique about this treatment is that only one dose may be required. In addition, a very small amount of product around 250 times less will be needed compared to other treatments on the market for retinal blindness, she adds.

Although the company only launched in June 2020, RainBio already has pre-clinical efficacy and safety data and is poised to meet with the US Food and Drug Administration.

Even though were not even a year old, we have orphan drug designation and rare pediatric disease designation that was granted to us by the FDA, says Martin. We have pre-clinical efficacy in theMPS1canine model, and 100 percent prevention and reversal of cornea blindness.

RainBio is developing aplatform for additional treatmentsfor blinding corneal diseases.

There are several Lysosomal storage diseases that have the same cornea blindness issue, says Martin. Although its a different gene that is missing, we believe as we prove this concept inMPS1patients, then it will be translatable to otherlysosomal storagediseases.

As RainBio continues to grow and develop its product, next steps include accessing additional funding to manufacture the product and get it into the clinic.

Link:
Breakthrough gene therapies in sight | UNC-Chapel Hill - UNC Chapell Hill

FDA’s Abecma Approval a ‘Great Blessing’ for Patients with Multiple Myeloma – Curetoday.com

The Food and Drug Administrations (FDA) recent approval of the first CAR-T cell therapy, Abecma (idecabtagene vicleucel), for the treatment of multiple myeloma is extremely significant for adults who have not responded to at least four lines of therapy, according to an expert from the Dana-Farber Cancer Institute.

I think this is extremely significant (because) now its real, Dr. Nikhil Munshi, director of basic and correlative science at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, said in an interview with CURE. To give an idea of when the studies were done, we knew (Abecma) worked very well, patients knew it worked very well. Now that it's commercially available, this is a real option for (patients).

In fact, Munshi noted, there has been a tremendous need for a CAR-T cell therapy in a heavily pretreated population with multiple myeloma.

In patients who have had a median of six prior lines of therapy, he highlighted, previously available therapies have induced response rates of 20% to 30%. With the highest target dose of Abecma, the overall response rate in the trial was approximately 82% and almost 40% of those patients had complete response to therapy, according to Munshi.

We are achieving deep responses as we had never hoped before, he said. And this is at a late stage. As we are beginning to now do studies that are earlier stage, we can only get better. So that's one component and the responses last.

Moreover, treatment with Abecma resulted in a progression-free survival (time from treatment initiation to disease progression, disease relapse or all-cause death) of about nine months compared to two to four months with other therapies.

I think there is a huge difference between what else is available in this space versus what we can get with (Abecma), he said. That doesn't mean what else is available is not useful, but now we have a very powerful, effective option available that we can give.

Just with any therapy, Munshi mentioned, there are some toxicities associated with the use of Abecma. The most common include cytokine release syndrome (CRS), which happens in approximately 90% of patients, and neurotoxicity. However, approximately 5% to 6% of CRS were serious or severe and around 3% of neurotoxicity were serious or severe.

Toxicities are there (and) are serious enough that we cannot take it lightly, he said. Patients would need some hospitalization most of the time for a short period, but it's very manageable.

Abecma has the potential to become a standard of care for a heavily pretreated population with multiple myeloma, according to Munshi. He likened it to cancer centers experienced in performing allogeneic stem cell transplants.

I do see that CAR-T (cell therapy) will not be restricted to 20 or 30 big centers like (Dana-Farber), where we do it enough, (but) it also will be in new course, done by reasonably medium-sized centers who can be equipped to do it, he said. Centers, which are currently doing transplant, in given time would be able to do CAR T and it would become reasonable standard of care.

Although the approval of Abecma is indicated for patients who have had at least four prior lines of therapy, there are multiple studies currently underway evaluating it in the second- and third-line setting, Munshi mentioned. Additionally, there is another study evaluating it in an upfront setting focusing on high-risk patients.

Its just a matter of time before the approvals are obtained for that phase of treatment, he said. It definitely belongs earlier on.

The approval is a great blessing for both physicians and patients, according to Munshi. He noted that Abecma is one therapy that leads to MRD negativity at a late stage and should as well at an earlier stage.

I believe this is the first step in the near future to a cure, he concluded.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read the original here:
FDA's Abecma Approval a 'Great Blessing' for Patients with Multiple Myeloma - Curetoday.com

Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in…

This article was originally published here

Prostate Int. 2021 Mar;9(1):31-41. doi: 10.1016/j.prnil.2020.07.002. Epub 2020 Jul 31.

ABSTRACT

BACKGROUND: This study investigated the inhibition of tumor growth in castrate-resistant prostate cancer (CRPC)-bearing mice by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-overexpressing adipose-derived stem cells (ADSCs) (hTERT-ADSC.sTRAIL), which was enhanced by combined treatment with CPT-11.

MATERIALS AND METHODS: An hTERT-ADSC.sTRAIL cell line was established by transfection with a lentiviral vector (CLV-Ubic) encoding the human sTRAIL gene. Quantitative polymerase chain reaction and Western blots were performed to confirm gene overexpression. An invasion study for the selective migration ability toward PC3 cells was performed. In the in vivo study, the tumor volume in mice treated with ADSC. sTRAIL and CPT-11 was measured.

RESULTS: Carboxylesterase was generated from hTERT-ADSCs. The gene expression of sTRAIL from hTERT-ADSC.sTRAIL was shown. The directional migration of ADSC.sTRAIL cells toward PC3 cells was significantly stimulated by PC3 cells in vitro (P < 0.05). In the in vitro study, the viability of PC3 cells significantly decreased in the presence of ADSC.sTRAIL (62.7 2.0%) and CPT-11 compared with that of CPT-11 alone (83.0 1.0%) at a cell ratio as low as 0.05 (PC3: ADSC.sTRAIL) (P < 0.05). The proportion of apoptotic PC3 cells significantly increased in the presence of ADSC.sTRAIL (37.2 2.1%) and CPT-11 compared with that of CPT-11 alone (16.5 1.0%) (P < 0.05). In the in vivo study, the inhibition of tumor growth in CRPC-bearing mice by TRAIL-overexpressing adipose stem cells was enhanced by combined treatment with the chemotherapeutic agent CPT-11 compared with that in the treatment with cpt-11 alone. Immunohistochemical staining of the removed tumors showed anti-TRAIL-positive cells and apoptotic bodies after hTERT-ADSC.sTRAIL treatment or combined treatment with hTERT-ADSC.sTRAIL and CPT-11.

CONCLUSIONS: Therapeutic stem cells expressing sTRAIL genes combined with CPT-11 can provide a new strategy for treating CRPC in clinical trials using the patients own ADSCs.

PMID:33912512 | PMC:PMC8053698 | DOI:10.1016/j.prnil.2020.07.002

Read the original here:
Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in...

Global Stem Cell Therapy Market 2020-2027 Trends, industry vertical, along with the geography, delivering valuable insights | Reportspedia Clark…

The Global Stem Cell Therapy Market Report is a complete and unique study of Stem Cell Therapys landscape structure. Initially, it gives us an overview of global market size and forecast, market characteristics, global and regional market size, market growth of Stem Cell Therapy market, production data, imports and exports statistics of Stem Cell Therapy industry are detailed in this study which is segmented by type, application, and consumption area of Stem Cell Therapy.

Find out how COVID-19 has affected the growth of the industry. Get a free sample report with detailed analysis @

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request-sample

This comprehensive report elaborates on the global Stem Cell Therapy market value growth trend from 2020 to 2027. This study is a fragmentary description of the Stem Cell Therapy structure to provide a complete consumer perspective and a complete analysis of the Stem Cell Therapy industry.

The next section or segment of the report provides a comprehensive analysis including information such as a detailed explanation of the product structure, the economic background of the market, dynamics of supply and demand, trade statistics, and product value analysis are analyzed in this report. The key development strategies plans and policies for the Stem Cell Therapy market are examined about their impact on the market in the forecast period.

The research report evaluates detailed historical data on product volume, capacity, demand, and supply chain logistics in the product market to assess the markets acute impact of the COVID-19 and pandemic epidemics. It analyzes the evolution of trends and considers recent developments that are likely to have an impact on market conditions in the coming period.

Do Inquiry Before Buying https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

This report is segmented into 3 segments i.e by type, application, and region

Based on type and applications this study presents vital information like market value, market share, growth rate, buyers, and consumption of Stem Cell Therapy from 2015-2020.

Market Segmentation:

Major Types covered,

Adult Stem Cells Human Embryonic Induced Pluripotent Stem Cells Very Small Embryonic Like Stem Cells

Major Applications covered,

Regenerative Medicine Drug Discovery and Development

Regions Covered in this research:

Regional Analysis

Download a free sample report with all tables and graphs

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request-sample

Under the segment industry chain structure, users will get information on upstream raw material suppliers of Stem Cell Therapy. Major players of Stem Cell Therapy, their market share, manufacturing base are also covered. The cost structure analysis explains the cost of raw materials involved in Stem Cell Therapy and labor cost. The marketing channels and downstream buyers of Stem Cell Therapy are described in this study.

The report answers some important questions:

Browse Full TOC, [emailprotected] https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table-of-contents

See the rest here:
Global Stem Cell Therapy Market 2020-2027 Trends, industry vertical, along with the geography, delivering valuable insights | Reportspedia Clark...

Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Global Key Players, Types, Applications, Countries, Size, Forecast to 2027 Clark County…

The recent report on Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, forecast to 2027 offered by Credible Markets, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Rheumatoid Arthritis Stem Cell Therapy Market.

An exhaustive competition analysis that covers insightful data on industry leaders is intended to help potential market entrants and existing players in competition with the right direction to arrive at their decisions. Market structure analysis discusses in detail Rheumatoid Arthritis Stem Cell Therapy companies with their profiles, revenue shares in market, comprehensive portfolio of their offerings, networking and distribution strategies, regional market footprints, and much more.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.crediblemarkets.com/sample-request/rheumatoid-arthritis-stem-cell-therapy-market-327877?utm_source=Komal&utm_medium=SatPR

Rheumatoid Arthritis Stem Cell Therapy market is segmentedBy Company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Rheumatoid Arthritis Stem Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

Allogeneic Mesenchymal Stem Cells

Bone Marrow Transplant

Adipose Tissue Stem Cells

Segment by Application

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Mesoblast

Roslin Cells

Regeneus

ReNeuron Group

International Stem Cell Corporation

Regional Analysis of Global Rheumatoid Arthritis Stem Cell Therapy Market

All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Rheumatoid Arthritis Stem Cell Therapy market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.

Direct Purchase this Market Research Report Now @ https://www.crediblemarkets.com/reports/purchase/rheumatoid-arthritis-stem-cell-therapy-market-327877?license_type=single_user;utm_source=Komal&utm_medium=SatPR

What does the Report Include?

The market report includes a detailed assessment of various drivers and restraints, opportunities, and challenges that the market will face during the projected horizon. Additionally, the report provides comprehensive insights into the regional developments of the market, affecting its growth during the forecast period. It includes information sourced from the advice of expert professionals from the industry by our research analysts using several research methodologies. The competitive landscape offers further detailed insights into strategies such as product launches, partnership, merger and acquisition, and collaborations adopted by the companies to maintain market stronghold between 2021 and 2027.

The report can answer the following questions:

North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Rheumatoid Arthritis Stem Cell Therapy industry.

Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Rheumatoid Arthritis Stem Cell Therapy industry.

Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Rheumatoid Arthritis Stem Cell Therapy industry.

Different types and applications of Rheumatoid Arthritis Stem Cell Therapy industry, market share of each type and application by revenue.

Global market size (sales, revenue) forecast by regions and countries from 2021 to 2027 of Rheumatoid Arthritis Stem Cell Therapy industry.

Upstream raw materials and manufacturing equipment, industry chain analysis of Rheumatoid Arthritis Stem Cell Therapy industry.

SWOT analysis of Rheumatoid Arthritis Stem Cell Therapy industry.

New Project Investment Feasibility Analysis of Rheumatoid Arthritis Stem Cell Therapy industry.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.crediblemarkets.com/enquire-request/rheumatoid-arthritis-stem-cell-therapy-market-327877?utm_source=Komal&utm_medium=SatPR

Contact Us

Credible Markets Analytics 99 Wall Street 2124 New York, NY 10005 Email:[emailprotected]Follow Us:LinkedIn|Twitter|Facebook

https://clarkcountyblog.com/

The rest is here:
Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Global Key Players, Types, Applications, Countries, Size, Forecast to 2027 Clark County...

CRISPRoff Reversible Epigenome Editing Method Could Enable Safer, More Precise Therapeutics – GenomeWeb

NEW YORK As CRISPR researchers develop new and better ways to edit the genome while leaving as few unintended consequences as possible behind, a team led by scientists at the University of California, San Francisco and MIT has developed a method that would create completely reversible gene edits.

In a recent study in Cell, UCSF's Luke Gilbert, MIT's Jonathan Weissman, and their colleagues described their method, called CRISPRoff a programmable epigenome editor consisting of a single dead Cas9 fusion protein that establishes DNA methylation and repressive histone modifications. This transient CRISPRoff expression initiates highly specific repression of genes and DNA methylation that's maintained through cell division and differentiation of stem cells to neurons. In their experiments, they found that the epigenome editing was highly specific, with minimal off-target editing.

In order to reverse this effect, the researchers then engineered a switch they called CRISPRon, through which they used Cas9-mediated gene editing to inactivate DNMT1 the main DNA methylation maintenance enzyme in mammalian cells in cells where they had previously silenced specific genes. Post-DNMT1 knockout, 60 percent to 80 percent of cells demonstrated reactivated gene expression. Similarly, treatment of cells with a small-molecule inhibitor of DNMT1 showed reactivated expression of genes that had previously been silenced, demonstrating that depletion of DNA methylation was sufficient to reverse CRISPRoff-mediated gene silencing.

"If you want to fix a pathogenic mutation, then CRISPR is really enabling. But we felt that for many applications, you may not want to permanently mutate the genome," Gilbert said, explaining the method's genesis. "So, we were searching for ways to turn gene expression off or on, without manipulating the sequence of the genome and just manipulating the transcripts that are produced by a cell."

Medically, he noted, there could be many applications where patients might feel more comfortable with using genome editing if they know that their genes won't be permanently changed, in part based on the concept that gene therapy has already been in use for a variety of applications for more than a decade.

Gilbert further noted that while he, Weissman, and many other CRISPR researchers have been working with tools such as CRISPR interference (CRISPRi) that can downregulate gene expression rather than turning it off entirely, these tools are more awkward to work with from a therapeutic standpoint. While a regular CRISPR-Cas system uses a Cas nuclease to latch onto a gene a mutate it in some fashion to turn it off, CRISPRi uses deactivated Cas9, resulting in RNA-directed transcriptional control of the target region. In other words, it functions "almost like normal transcription factors within a cell, where you constitutively express proteins to target the gene, and then that turns the gene on or off," Gilbert explained. "One of the advantages of Cas9 is you can express it briefly and it'll make a change to the genome that's permanent, and carry it out for a long time. We were looking for ways to basically leverage the strengths of Cas9's permanence and durability, but also leverage this epigenetic editing feature of not having to permanently mutate a gene."

The dead Cas9 works as a programmable DNA binding element rather than as a programmable nuclease, Weissman added.

In terms of therapeutic applications for human beings, the technology has a lot of possible uses, the researchers believe. Before there was an Ebola vaccine, for example, they were working on CRISPRoff as a way to confer programable immunity for anyone who might be affected by the disease.

"If you have a virus where you know the receptor, you could use CRISPRoff to turn gene expression off," Gilbert said. For Ebola that receptor is a protein called NPC1. "We know if you turn NPC1 off in the liver, you're immune to Ebola. But you don't want to permanently mutate NPC1 because you cause cholesterol processing defects and lysosomal storage disorder phenotypes," he added. The idea they had, therefore, was to deliver CRISPRoff to the liver of healthcare workers traveling to Ebola hotspots so that they'd be completely immune to the disease while working with patients.

"And when they left the Ebola hotspot, to avoid detrimental effects of mutating or permanently silencing NPC1, then you could redeliver CRISPRon to restore gene expression and therefore not have any detrimental phenotypes from permanently losing that gene function," Gilbert added.

He further noted that the technology could even be used to modulate pain response. If someone were planning to have surgery, or recovering from an injury, CRISPRoff could be administered to shut down pain receptors for a short time. Once the patient recovered, the pain receptors could be turned back on. It would also help people avoid opioid pain killers.

Another example, according to Weissman, would be in the area of oncology. Cancer studies often reveal the presence of genes or gene mutations that lead to resistance to chemotherapy or radiotherapy. CRISPR is now being considered as a possible addition to some late-stage cancer patients' therapies as a way to knock out resistance genes and reawaken therapeutic response.

In May 2019, Christiana Care's Health System's Gene Editing Institute was preparing to file an investigational new drug application with the US Food and Drug Administration for a clinical trial protocol that would use CRISPR genome editing to improve the efficacy of chemotherapy for KRAS-positive non-small-cell lung cancer (NSCLC) patients. The protocol involved using CRISPR-Cas9 gene editing to knock down NRF2 in order to render patients more sensitive to chemotherapeutic agents.

Under a scenario using CRISPRoff, that gene's expression may only be off for the time it takes to administer the necessary cancer treatment. "You can imagine turning on or off genes in your intestine or in your blood stem cells," Weissman said. "The cells are more sensitive to radiation. But then after you have the radiotherapy, [the cells could return] to normal states so you don't have to worry about the long-term consequences of turning off the gene."

Weissman noted there may be some instances where CRISPRon isn't needed to turn gene expression back on. While conducting their experiments, the researchers noted that the gene silencing in certain loci would decay over a period of days or weeks, depending on the cell cycle turnover rate.

"If that can be tuned, we can now come in [with] one type of treatment and over the period of, say, weeks or months, it would naturally restore and you don't have to come in with the second," Weissman said.

That rate of decay would depend on the tissue in question and the dynamics of tissue turnover "will dictate how long these program changes last," Gilbert added. "In post-mitotic cells like muscle or neuron, these methyl marks in non-replicating cells may last for years and years. So, it depends on the cell type."

There are still many elements to CRISPRoff that have to be worked out and refined before it can be used in the clinic. As with any CRISPR system meant to be used as a therapy, delivery into the right cells at the right time is currently the principal challenge, Gilbert said. The researchers are also working on making the CRISPRoff complex smaller, and capable of targeting more than one loci at once, Weissman added.

But there's already been clear interest in commercializing the technology, he said. Both he and Gilbert, as well as a few other researchers who authored the paper, have already filed for patents on CRISPRoff and CRISPRon.

Indeed, Weissman said, the technology could have applications in cell therapy, and could even aid in the development of so-called off-the-shelf allogeneic CAR-T cells. The current procedure for making CAR Ts is expensive and time-consuming because it involves harvesting an individual's cells, engineering them, and re-administering them as a treatment. As of now, allogeneic CAR Ts could cause life-threatening graft-versus-host disease, and could be rejected by the host immune system.

Using CRISPRoff, however, Weissman envisions being able to edit allogeneic CAR Ts in ways that would camouflage them from an individual's immune system, while also adding safety controls that would allow a physician to turn the CAR Ts off, if needed. "It could make it a much more accessible treatment," he said. "You could have a safer and more universal cell therapy, and you can then do much more complicated engineering because you only have to do it once for many patients, as opposed to trying to do this complicated engineering in a bespoke way for each patient."

Overall, he added, what the study really shows is that cutting DNA and then repairing it is quite difficult. And while researchers have gotten better at avoiding off-target effects, so-called on-target off-targets unintended consequences of on-targets editing such as DNA damage response, large indels, and even chromothripsis, can still do damage to the genome.

"So, when you don't have to do that, therapeutically, there are lot of advantages," Weissman said. "Things like base editor and prime editor are examples of this, and we see CRISPRoff as a complement to this, which allows you to do epigenome editing from beginning to end, and to do it in a clean and controlled way."

See the article here:
CRISPRoff Reversible Epigenome Editing Method Could Enable Safer, More Precise Therapeutics - GenomeWeb

Cell Therapy Market To Expand At An expeditious Growth Rate From 2021-2027 | Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,…

Adroit Market Research has added a detailed study on the Cell Therapy market which provides a brief summary of the growth trends influencing the market. The global Cell Therapy market study offers a thorough examination of economic growth, technical advances, and a practical evaluation of technology suppliers. In the global Cell Therapy market analysis, on-demand triggers, vulnerabilities, and other factors such as fluctuating production rates, R&D spending, and organizational difficulties are all clear.

The report delivers detailed market segmentation, such as shape, functionality, and geographic regions, is a major focus of global Cell Therapy market research.

Request for Free Sample Research Report on Cell Therapy Market @ https://www.adroitmarketresearch.com/contacts/request-sample/611?utm_source=AD

(The free sample report is updated with new research additions and quickly available on request).

The annual Cell Therapy market report looks at a variety of tactics used by leading service companies, such as mergers and acquisitions, alliances, deals, and other approaches. Market size, market growth factors, and market segmentation are all examined in detail in the Cell Therapy market research report.

The factors that have fueled and hampered the development of the Cell Therapy industry are also examined in this market research study. The global business analysis provides key perspectives on core developed economies and developing markets, depending on the regional development of the Cell Therapy market. The industrys national and regional breakdowns, growth size, as well as its dynamics, consumer positions, trends and policies, industry segmentation, and the ever-shifting global market condition, are all examined in the Cell Therapy industry review. The research overview also traces the previous industrys Cell Therapy as well as the global markets projected value dependent on geographic analysis.

Cell Therapy Market by leading Manufacturers (2021-2026):

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost

Browse complete report with in-depth TOC @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market?utm_source=AD

The global Cell Therapy industry research study compares economies and national demographics in order to understand the significance of the Cell Therapy sector in a changing regional scenario. The global Cell Therapy industry report also looks at the number of technological advancements that have arisen in recent years, as well as how quickly they have been embraced. The aim analysis report also includes a concise market segmentation environment and a diagram of the Cell Therapy industrys regional scenario. This study also covers the type, implementation, end-user industry, and regions, which include Europe, North America, Asia Pacific, MEA, and the Rest of the World.

Global Cell Therapy Market Trends: By Product

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Major Reasons to purchase this Report:

The global Cell Therapy report also provides an extensive study of the strategies adopted by new and prominent service providers.

This study goes into great detail about competitive opportunities, driving forces, market limitations, and research and development.

It covers technological developments, growth potential, key trends, and market dynamics.

In terms of the geographic perspective, the Cell Therapy market research report delivers concise research of

Key perspectives across a range of technologies and applications markets.

Major Points Covered in TOC:

Overview: Along with a broad overview of the Cell Therapy market, this section gives an overview of the report to give an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the Cell Therapy market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the Cell Therapy market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Cell Therapy market.

Regional Growth Analysis: All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Cell Therapy market. Market participants can use this analysis to make strategic investments in key growth pockets of the Cell Therapy market.

You can also get individual chapter wise section or region wise report versions like North America, Europe or Asia or Country like US, UK, China and other.

Inquire more before buying this report Here @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611?utm_source=AD

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

View post:
Cell Therapy Market To Expand At An expeditious Growth Rate From 2021-2027 | Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,...